135 related articles for article (PubMed ID: 2841334)
1. Expression of functional human C1 inhibitor in COS cells.
Eldering E; Nuijens JH; Hack CE
J Biol Chem; 1988 Aug; 263(24):11776-9. PubMed ID: 2841334
[TBL] [Abstract][Full Text] [Related]
2. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
de Agostini A; Patston PA; Marottoli V; Carrel S; Harpel PC; Schapira M
J Clin Invest; 1988 Aug; 82(2):700-5. PubMed ID: 2457036
[TBL] [Abstract][Full Text] [Related]
3. The balance between inhibition and substrate-type reactions of recombinant C1 inhibitor P5/P3 variants.
Eldering E; Huijbregts CC; Nuijens JH; Hack CE
Behring Inst Mitt; 1993 Dec; (93):125-30. PubMed ID: 8172559
[No Abstract] [Full Text] [Related]
4. Characterization of recombinant C1 inhibitor P1 variants.
Eldering E; Huijbregts CC; Lubbers YT; Longstaff C; Hack CE
J Biol Chem; 1992 Apr; 267(10):7013-20. PubMed ID: 1551909
[TBL] [Abstract][Full Text] [Related]
5. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
[TBL] [Abstract][Full Text] [Related]
6. C1 inhibitor: analysis of the role of amino acid residues within the reactive center loop in target protease recognition.
Zahedi R; MacFarlane RC; Wisnieski JJ; Davis AE
J Immunol; 2001 Aug; 167(3):1500-6. PubMed ID: 11466370
[TBL] [Abstract][Full Text] [Related]
7. alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
Sulikowski T; Bauer BA; Patston PA
Protein Sci; 2002 Sep; 11(9):2230-6. PubMed ID: 12192078
[TBL] [Abstract][Full Text] [Related]
8. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms.
Davis AE; Aulak K; Parad RB; Stecklein HP; Eldering E; Hack CE; Kramer J; Strunk RC; Bissler J; Rosen FS
Nat Genet; 1992 Aug; 1(5):354-8. PubMed ID: 1363816
[TBL] [Abstract][Full Text] [Related]
9. The regulation of human factor XIIa by plasma proteinase inhibitors.
Pixley RA; Schapira M; Colman RW
J Biol Chem; 1985 Feb; 260(3):1723-9. PubMed ID: 2578463
[TBL] [Abstract][Full Text] [Related]
10. Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s.
Prandini MH; Reboul A; Colomb MG
Biochem J; 1986 Jul; 237(1):93-8. PubMed ID: 3099750
[TBL] [Abstract][Full Text] [Related]
11. Baculovirus-mediated expression of truncated modular fragments from the catalytic region of human complement serine protease C1s. Evidence for the involvement of both complement control protein modules in the recognition of the C4 protein substrate.
Rossi V; Bally I; Thielens NM; Esser AF; Arlaud GJ
J Biol Chem; 1998 Jan; 273(2):1232-9. PubMed ID: 9422791
[TBL] [Abstract][Full Text] [Related]
12. Proteolysis and deglycosylation of human C1 inhibitor. Effect on functional properties.
Reboul A; Prandini MH; Colomb MG
Biochem J; 1987 May; 244(1):117-21. PubMed ID: 3311024
[TBL] [Abstract][Full Text] [Related]
13. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
Donaldson VH; Wagner CJ; Tsuei B; Kindness G; Bing DH; Harrison RA; Rosen FS
Blood; 1987 Apr; 69(4):1096-101. PubMed ID: 3493816
[TBL] [Abstract][Full Text] [Related]
14. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model.
Bos IG; van Mierlo GJ; Bleeker WK; Rigter GM; te Velthuis H; Dickneite G; Hack CE
Int Immunopharmacol; 2001 Aug; 1(8):1583-95. PubMed ID: 11515821
[TBL] [Abstract][Full Text] [Related]
15. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats.
de Smet BJ; de Boer JP; Agterberg J; Rigter G; Bleeker WK; Hack CE
Blood; 1993 Jan; 81(1):56-61. PubMed ID: 8417802
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.
Brower MS; Harpel PC
J Biol Chem; 1982 Aug; 257(16):9849-54. PubMed ID: 6980881
[TBL] [Abstract][Full Text] [Related]
17. Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status.
Skriver K; Wikoff WR; Patston PA; Tausk F; Schapira M; Kaplan AP; Bock SC
J Biol Chem; 1991 May; 266(14):9216-21. PubMed ID: 2026621
[TBL] [Abstract][Full Text] [Related]
18. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassays.
Nuijens JH; Huijbregts CC; Cohen M; Navis GO; de Vries A; Eerenberg AJ; Bakker JC; Hack CE
Thromb Haemost; 1987 Aug; 58(2):778-85. PubMed ID: 2445044
[TBL] [Abstract][Full Text] [Related]
19. Effect of reactive site loop elongation on the inhibitory activity of C1-inhibitor.
Bos IG; Lubbers YT; Eldering E; Abrahams JP; Hack CE
Biochim Biophys Acta; 2004 Jun; 1699(1-2):139-44. PubMed ID: 15158721
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human complement subcomponent C1s lacking beta-hydroxyasparagine, sialic acid, and one of its two carbohydrate chains still reassembles with C1q and C1r to form a functional C1 complex.
Luo C; Thielens NM; Gagnon J; Gal P; Sarvari M; Tseng Y; Tosi M; Zavodszky P; Arlaud GJ; Schumaker VN
Biochemistry; 1992 May; 31(17):4254-62. PubMed ID: 1533159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
